Results 11 to 20 of about 27,235 (300)
Design and Production of Bispecific Antibodies [PDF]
With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy.
Qiong Wang+7 more
doaj +4 more sources
Bispecific antibodies in cancer immunotherapy [PDF]
Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and ...
Eva Dahlén+2 more
doaj +3 more sources
Bispecific antibodies for viral immunotherapy [PDF]
Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies.
Elisabeth K. Nyakatura+2 more
doaj +4 more sources
Bispecific antibodies in follicular lymphoma
Bispecific antibodies, specifically anti-CD20 T-cell engaging constructs, are poised to alter the treatment paradigm of multiple B-cell malignancies, including follicular lymphoma.
Imran A. Nizamuddin, Nancy L. Bartlett
doaj +3 more sources
Bispecific antibodies and their applications [PDF]
Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.
Mingju Hao+3 more
openaire +3 more sources
The making of bispecific antibodies [PDF]
During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibodies, molecules with an IgG ...
Ulrich Brinkmann, Roland E. Kontermann
openaire +3 more sources
Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique+2 more
openaire +3 more sources
Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies. [PDF]
Recently, bispecific antibodies (BsAbs) are evolving the landscape of cancer treatment and have significantly improved the outcomes of relapsed or refractory cancer patients. As increasing BsAbs entered clinical practice, specific toxicities have emerged, and renal side-effects have been described.
Wen X, Xu G.
europepmc +3 more sources
Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire +3 more sources
Broadly neutralizing antibodies (bNAbs) can prevent and control an HIV-1 infection, but their breadth is invariably too limited for use as monotherapy. To address this problem, bi- and trispecific antibody-like constructs have been developed.
Meredith E. Davis-Gardner+4 more
doaj +1 more source